BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024

BioVie Inc. announced data from presentations at the ATMRD Congress, outlining the protocol design of SUNRISE-PD Phase 2 trial for bezisterim in Parkinson's disease.